U.S. Markets closed

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.1600-0.1300 (-3.95%)
At close: 04:00PM EDT
3.1600 0.00 (0.00%)
After hours: 04:49PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.2900
Bid2.5500 x 1300
Ask3.1800 x 1200
Day's Range2.9600 - 3.2700
52 Week Range2.0600 - 8.1400
Avg. Volume56,709
Market Cap229.583M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease

    AC Immune’s Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer’s Disease (AD)AC Immune to receive a milestone payment from LMI for progress into late-stage product development LAUSANNE, Switzerland, Sept. 26, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its partner, Life Molecular Imaging (LMI), is moving PI-2620, the Tau positron-

  • GlobeNewswire

    AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent

    Previously reported clinical proof-of-concept data on ACI-12589 showed the PET tracer generating the first live images of alpha-synuclein in the human brainNew grant funding will pave the way for enhanced clinical studiesTotal funding from The Michael J. Fox Foundation for AC Immune’s alpha-synuclein PET tracer program is now up to USD 3.7 million LAUSANNE, Switzerland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision

  • GlobeNewswire

    AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases

    Vaccines can provide safe, long-lasting immunity, and logistical advantages compared to other treatment modalitiesIntegrating its precision medicine approach, AC Immune is advancing three clinical-stage vaccines targeting Tau, Abeta and α-synucleinPrecisely targeted active immunotherapy may enable prevention of pathological pathways before the occurrence of irreversible neuronal damage LAUSANNE, Switzerland, Aug. 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharm